At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Position Summary
We are seeking a highly motivated Scientist to be part of the TM CBIMS internship program. The TM CBIMS (Clinical Biomarker Immunoassay & Mass Spec) group utilize the most cutting edge biomarker technology to support a wide range of clinical trials for BMS drug development in areas including oncology, immuno-sciences, cardiovascular, and fibrosis. During this internship the candidate will learn how protein immunoassays and mass spec are used in aiding drug development. The candidate will also gain hands-on experience in designing and executing biomarker studies using a wide range of existing and novel technologies to support BMS drug development.
Bristol-Myers Squibb is the industry leader in immuno-oncology and innovative medicines in fibrosis, immune-sciences and cardiovascular diseases. The candidate will have the opportunity to participate in discussions and planning of biomarker analysis for various disease types.
Key Responsibilities
* Directly contribute to development of methods for protein biomarker characterization.
* Contribute to establishment of lab workflows for protein biomarkers analysis.
* Contribute to efforts to explore the utility of the novel technology in clinical biomarker development.
* Participate in group activity to publish research data in posters (internal and external to BMS) with a goal to participate in a high quality publication.
Qualifications & Experience
* Undergraduate (entering Junior year or above in the Fall of 2021) with 1-2 years of relevant lab experience in molecular biology, biochemistry or cell biology.
* Strong understanding of cell and molecular biology theory and experimental practices.
* Excellent communication skills, both written and verbal are required.
* Proactive at keeping current with literature and reading deeply about field of application.
* Ability to think outside the box and innovate.
BMSEC, BMSINTERN
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.